Nasal polyps

SINUVA™ (mometasone furoate) sinus implant, a nonsurgical targeted nasal polyp treatment option​ for adult patients with CRS who have had ethmoid sinus surgery

SINUVA woman on bike


 

About nasal polyps

The road to symptom relief can be difficult​

Nasal polyps develop by intrinsic mucosal inflammation that persists in the ethmoid sinuses1.​

Symptoms include:​

Sense of smell

Decreased or absent sense of smell​
Runny nose

Runny nose/post-nasal discharge​
Facial pain

Facial pain/pressure​
Sinus congestion

Nasal obstruction/congestion​

Understanding the cyclical nature of nasal polyps​

Patients who fail to achieve symptom relief with medication management turn to endoscopic sinus surgery (ESS)​

​Patients with nasal polyps require revision ESS more frequently than patients who do not have nasal polyps2,3​

Map

>500,000 ESSs
are performed in the US annually4


40%

Despite surgery, polyp reappearance was 35% at six months and 40% at 18 months.6


60%

Patients who undergo ethmoid sinus surgery have symptoms reappear within one year of surgery.5


2 in 5

Two in five patients may have polyp recurrence at 18 months.7,8

Challenges of sinus surgery​

Despite the use of steroids and endoscopic sinus surgery, recurrence of nasal polyps is common due to the inflammatory nature of the disease, resulting in the need for repeat surgery in patients over time.2

symptoms graph

Different challenges

  1. Ethmoid sinus surgery
  2. Post-op management with steroids
  3. Polyp recurrence
  4. Nasal obstruction + congestion

Learn more on SINUVA™​ sinus implant

  

Referenced path does not exist

1

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1–S39.

2

Hull BP, Chandra RK. Refractory Chronic Rhinosinusitis with Nasal Polyposis. Otolaryngol Clin North Am. 2017;50(1):61–81.

3

Stein NR, Jafari A, DeConde AS. Revision rates and time to revision following endoscopic sinus surgery: A large database analysis. Laryngoscope. 2018;128(1):31–36.

4

Data on File. MRG 2012 US Markets for ENT and Bronchoscopy.​

5

Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811–813.

6

DeConde AS, Mace JC, Levy JM, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550–555.​

7

SINUVA™ [Prescribing Information]. Menlo Park, CA: Intersect ENT; 2023.​

8

Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol. 2012;22(1):1–12.​